Sergio Rosales-Mendoza1, Cristhian Sández-Robledo2, Bernardo Bañuelos-Hernández3, Carlos Angulo2. 1. Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí, SLP, 78210, Mexico. rosales.s@fcq.uaslp.mx. 2. Centro de Investigaciones Biológicas del Noroeste, SC, Instituto Politécnico Nacional 195, Playa Palo de Santa Rita Sur, La Paz, BCS, 23096, Mexico. 3. Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí, SLP, 78210, Mexico.
Abstract
MAIN CONCLUSION: Corn is an attractive host for vaccine production and oral delivery. The present review provides the current outlook and perspectives for this field. Among seed-crops, corn represents a key source of biomass for food, fuel production, and other applications. Since the beginning of the development of plant-based vaccines, corn was explored for the production and delivery of vaccines. About a dozen of pathogens have been studied under this technology with distinct degrees of development. A vaccine prototype against enterotoxigenic Escherichia coli was evaluated in a phase I clinical trial and several candidates targeting bacterial and viral diseases are under preclinical evaluation. The present review provides an updated outlook on this topic highlighting the employed expression strategies; perspectives for the field are also provided.
MAIN CONCLUSION: Corn is an attractive host for vaccine production and oral delivery. The present review provides the current outlook and perspectives for this field. Among seed-crops, corn represents a key source of biomass for food, fuel production, and other applications. Since the beginning of the development of plant-based vaccines, corn was explored for the production and delivery of vaccines. About a dozen of pathogens have been studied under this technology with distinct degrees of development. A vaccine prototype against enterotoxigenic Escherichia coli was evaluated in a phase I clinical trial and several candidates targeting bacterial and viral diseases are under preclinical evaluation. The present review provides an updated outlook on this topic highlighting the employed expression strategies; perspectives for the field are also provided.
Authors: Rachel K Chikwamba; M Paul Scott; Lorena B Mejía; Hugh S Mason; Kan Wang Journal: Proc Natl Acad Sci U S A Date: 2003-09-05 Impact factor: 11.205
Authors: Maan T Khayat; Mohamed A Zarka; Dalia Farag A El-Telbany; Ali M El-Halawany; Hussam Ibrahim Kutbi; Walid F Elkhatib; Ayman M Noreddin; Ahdab N Khayyat; Rania Farag A El-Telbany; Sherif F Hammad; Ashraf B Abdel-Naim; Ebtesam M Alolayan; Majid Mohammad Al-Sawahli Journal: Sci Rep Date: 2022-09-08 Impact factor: 4.996